TABLE 2.

Epitope sequence comparisons of strain A and strain Ba

Recognized peptidePresumed epitope (HLA)Epitope locationSequence for strain A and strain BΔCTL
LKETINEEAAEWDRVEEAAEWDRV (B*40)cGag 207-215 (p24)EEAAEWDRL
EEAAEWDRL
INEEAAEWDRVHPVH ....AAEWDRVHPVHAGPIAEWDRVHPV (B*40)bGag 210-218 (p24)AEWDRLHPV
AEWDRLHPV
PGQMREPRGSDIAGTUnknown(Gag 225-239 [p24])(PGQMREPRGSDIAGT)±
(PGQMREPRGSDIAGT)
EPIDKELYPLTSLRSKELYPLTSL (B*40)bGag 481-489 (p6)KELYPLASL
RGIDKELYPLASLd
EVGFPVRPQVPLRPMFPVRPQVPL (B*35)bNef 68-76FPVRPQVPL
FPVRPQVPL
PGPGIRYPLTFGWCF ....IRYPLTFGWCFKLVPYPLTFGWCF (B*35)b or RYPLTFGWCF (A*24)bNef 135-143 or 134-143YPLTFGWCF or RYPLTFGWCF
YPLCFGWCF or RYPLCFGWCF
KCCFHCQVCFTTKGLUnknown(Tat 29-43)(OCCFHCQVCFITKGL)
(KCCLHCQVCFTRKGL)
DEELLKTVRLIKFLY ....LKTVRLIKFLYQSNPTVRLIKFLY (A*03)cRev 15-23TVKIIKFLY
TVRLIKFLY
YWGLHTGERDWHLGQ ....HTGERDWHLGQGVSIHTGERDWHL (B*35)cVif 73-81HPGERDWHL
HTGERDWHL
  • a For peptides recognized in the ELISPOT assay at a frequency of at least 100 SFC/106 CD8+ T lymphocytes, the following are listed: the presumed epitope and its location, the sequence of the epitope in strain A (top) and strain B (bottom; differences from the screening sequence are shown in underlined boldface type), and the change of the CTL response following superinfection. Putative locations and sequences are shown in parentheses. ↓, Present before superinfection and waned after superinfection; ↑, present only after superinfection; ↔, persisting before and after superinfection; ±, present early but waned before superinfection.

  • b Previously reported epitope consistent with subject's known HLA type (A*03, A*24, B*35, B*40).

  • c Inferred from the HLA binding motifs of the subject's known HLA type.

  • d Insertion of four amino acids.